Despite a strong statistical correlation between our immunostaining results and prognostic factors of importance in astrocytoma tumour progression, further study is necessary before p53 immunostaining is routinely used in a prospective clinical setting. This evidence concerns the gene TP53 and astrocytoma (excluding glioblastoma).